Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
Soligenix reported a Q2 2026 net loss of $2.0 million, or ($0.12) per share, compared to a loss of $2.7 million in the prior year, with no revenue recognized in either period. The company confirmed the discontinuation of its HyBryte program following the Phase 3 FLASH2 trial outcome, resulting in reduced R&D expenses and a cash balance of $9.8 million extending runway into Q2 2028.
Key figures
- Revenue
- 0
- Net loss
- $2.0 million
- Ga expenses
- $1.1 million
- Rd expenses
- $1.0 million
- Cash position
- $9.8 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.